Moleculin Biotech, Inc. (MBRX) Total liabilities 2016–2025
Moleculin Biotech, Inc. (MBRX) total liabilities at each fiscal year-end, per SEC filings.
$7.1MFY2025 · since FY2016: $1.4M → $7.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $7.1M | +24.5% |
| FY2024 | $5.7M | -52.9% |
| FY2023 | $12.1M | +132.2% |
| FY2022 | $5.2M | +2.6% |
| FY2021 | $5.1M | -54.8% |
| FY2020 | $11.3M | +16.6% |
| FY2019 | $9.7M | +81.9% |
| FY2018 | $5.3M | +124.7% |
| FY2017 | $2.4M | +65.0% |
| FY2016 | $1.4M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More MBRX financial trends
MBRX RevenueMBRX Net incomeMBRX Net marginMBRX Gross profitMBRX Gross marginMBRX Operating incomeMBRX Operating marginMBRX Operating cash flowMBRX Free cash flowMBRX Capital expendituresMBRX Return on equityMBRX Stock buybacksMBRX Dividends paidMBRX Total assetsMBRX Shareholders’ equityMBRX overview →